AD Portfolio View
4 pipeline assets in Atopic Dermatitis — explore scenarios, compare outcomes, make portfolio decisions.
Portfolio Peak Revenue
Active Scenarios
of 10 available
Avg. Portfolio PoS
Cumulative probability
AI Challenges
Requires attention
Portfolio Forecast — Stacked by Asset
AI Strategic Critic
4 challengesYour assumption:
KP-723 achieves 7% Rx share at maturity in moderate AD
Your access tightening scenario contradicts this share projection. Oral agents face step therapy barriers in >60% of commercial plans. Historical JAKi launches show payer-driven share erosion of 30-40% vs initial projections.
Your assumption:
NM-26 uptake reaches 9% share with best-in-class itch positioning
This segment is unlikely to be fully owned by dual IL-4Rα/IL-31 MOA. Nemolizumab (pure IL-31Rα) launches 3 years earlier with established itch data. Historical patterns show first-mover advantage in pruritus captures 60% of segment share.
Scenario Library
KP-723 TPP Underperformance
Oral STAT6i fails to differentiate vs JAK1i on efficacy; limited to convenience positioning only
Dupixent Biosimilar Acceleration
Biosimilar Dupixent launches early (2031 EU, 2032 US), expanding market but compressing pricing
JAK Safety Signal Escalation
New JAK class safety data triggers further prescribing restrictions, shifting patients to biologics
Access Tightening (Payer Suppression)
Prior authorization requirements expand; step therapy enforced across new entrants
NM-26 Best-in-Class Itch Data
Phase 2 data shows unprecedented itch control via dual IL-4Rα/IL-31 blockade; differentiated positioning
PX-128 Asthma Co-indication
PX-128 IL-13/TSLP bispecific achieves asthma co-indication, doubling addressable market
MFN Policy Implementation
Most Favored Nation pricing implemented; US prices benchmarked to international reference
PX-130 Clinical Delay (2 years)
Preclinical-to-Phase 1 transition delayed; IND pushes approval to 2035
Competitive OX40 Breakthrough
Rocatinlimab achieves disease-modifying claim; shifts treatment paradigm away from cytokine blockade
Pediatric Indication Fast-Track
FDA grants pediatric priority review for NM-26 and KP-723; 2-year earlier pediatric access